PSMAI cut-off value for mortality in men: 680.1 mm2/m2
Por um escritor misterioso
Descrição
ASCO GU 2022: Predicting the Outcome of mCPRC Patients after Lu-177 PSMA Therapy Using Semi-Quantitative and Visual Criteria in Baseline PSMA PET: An International Multicenter Retrospective Study
Cancers, Free Full-Text
The Current Landscape of PSMA PET Imaging in Prostate Cancer: Advanced Prostate Cancer
The Current Landscape of Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy
PDF) The association between psoas muscle area index and morbidity/mortality in laparoscopic gastric cancer surgery
Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study
Frontiers Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - (ILCN/WCLC)
ASCO 2023: LuPARP: Phase 1 Trial of 177Lu-PSMA-617 and Olaparib in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years
SARCLISA® (isatuximab-irfc) ICARIA-MM Phase 3 Trial Results
Dual-Time-Point Posttherapy 177Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome
Computed tomographic images at the the middle third lumbar vertebral
PSMAI cut-off value for mortality in men: 680.1 mm2/m2
